Further evidence for the favorable effect of these drugs in BRAF-mutated thyroid carcinoma cells derives from the observation that treatment with PLX4032 and PLX4720 in BRAF-mutated thyroid carcinoma cells, but not in normal thyroid cells, decreases the phosphorylation of ERK1/2 and MAPK kinase (MEK)1/2. This evidence concerns the gene MAP2K1 and thyroid gland carcinoma.